Bharat Parenterals reported a robust Q2 FY27 with consolidated revenue rising 110.9% to Rs 136.28 crore. The performance was bolstered by a significant turnaround in subsidiary Innoxel Lifesciences, which turned profitable and successfully initiated US exports. While standalone operations and Varenyam Healthcare showed strong growth, management remains cautious regarding raw material inflation impacting margins and continues to push forward with its Rs 300 crore capital expenditure for the Varenyam Biolifesciences facility.
Bharat Parenterals Reports Massive 110% Revenue Growth in Q2
Consolidated revenue for Q2 FY27 reached Rs 136.28 crore, up from the previous year. Net profit stood at Rs 11.82 crore for the quarter.
Reader Takeaway: Strong revenue growth and subsidiary turnaround are key positives, though raw material inflation poses risks to margins.
What just happened
Bharat Parenterals announced strong financial results for the quarter ending September 30, 2026. The company saw a 110.9% year-on-year surge in consolidated revenue. A standout development was the performance of its subsidiary, Innoxel Lifesciences, which recorded a 253.1% revenue increase and shifted from a loss of Rs 11 crore in the previous year to a profit of Rs 5.45 crore this quarter. Additionally, the company marked a milestone with its first US export shipment on October 20, 2026.
Why this matters
The company’s strategic push into high-growth areas like oncology and biologics, combined with the successful entry into the US market via CMO arrangements, signals a shift toward higher value-added operations. The turnaround of Innoxel is a significant contributor to the current bottom-line improvement.
What changes now
Management has increased the capital expenditure for the Varenyam Biolifesciences facility at Savli to Rs 300 crore. This investment aims to expand capabilities in biologics and biosimilars. Guidance remains stable for all business units, targeting double-digit growth and healthy EBITDA margins for FY27.
Risks to watch
Investors should closely track the impact of raw material inflation, which management noted has already pressured gross margins. Additionally, the scale of future earnings at Innoxel remains dependent on the timely execution of its manufacturing ramp-up and the receipt of anticipated licensing income.
What to track next
Watch for updates on the construction progress of the Savli facility and further export updates from the US market, which serve as key growth levers for the medium term.